Risk Of Developing Liver Cancer After HCV Treatment

Sunday, November 13, 2016

AASLD 2016 Once-Daily Simeprevir, AL-335, and Odalasvir Combination Safe, Effective

Once-Daily Simeprevir, AL-335, and Odalasvir Combination Safe, Effective
By Bryant Furlow November 13, 2016

BOSTON, MA—Once-daily-administered combination of the investigative direct-acting antivirals AL-335 and odalasvir (ODV), and simeprevir (SMV) is well tolerated in healthy volunteers, and is now under study among patients with hepatitis C virus (HCV), according to findings from an open-label Phase 1 study presented at The Liver Meeting® 2016.
Continue reading.....

Additional updates @ MPR
Current updates: Conference Reports
Updates On This Blog: AASLD 2016



No comments:

Post a Comment